BlueWind Medical Ltd.

BlueWind Medical manufactures Revi, an implantable neuromodulation device for the treatment of urge urinary incontinence (UUI). Revi is a miniature implant positioned near the ankle that delivers tibial nerve stimulation to modulate bladder control signals. The device is implanted during a single outpatient procedure under local anesthesia and offers personalized, patient-controlled therapy requiring as little as 30 minutes daily. Clinical data from the OASIS study (NCT03596671, 3-year follow-up) demonstrates 95% patient satisfaction and 79% of study completers achieving greater than 50% reduction in incontinence episodes. Revi represents a drug-free alternative to pharmacological and surgical interventions for overactive bladder. The company has received regulatory clearance and recognition, including the 2025 MedTech Breakthrough Award for Best New Technology Solution in Therapeutics. BlueWind's technology addresses a significant market of patients with urge incontinence, offering a reversible, minimally invasive solution with demonstrated long-term safety and efficacy profiles suitable for outpatient urology and continence specialty practices.